{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-042631","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2023-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.289339+00:00","generated_at":"2026-06-11T09:34:39.171074+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Galecto's Phase 2b GALACTIC-1 trial misses primary endpoint; GB0139 discontinued","bullets":["GALACTIC-1 trial did not meet primary endpoint of FVC decline; change from baseline -316.6 mL vs -127.4 mL (placebo).","Serious adverse events: 7.8% in GB0139 arm vs 1.4% placebo; worsening IPF observed.","Cash and investments ~$49M as of July 31, 2023; evaluating resource allocation to extend runway into 2025.","Shifting focus to liver diseases; GULLIVER-3 Phase 2a trial of GB1211 expected to start early 2024.","No confirmation of target engagement; galectin-3 levels increased in both arms from day 0 to week 52."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-042631","json":"https://secwatch.observer/filing/0000950170-23-042631.json","markdown":"https://secwatch.observer/filing/0000950170-23-042631.md","text":"https://secwatch.observer/filing/0000950170-23-042631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023042631/0000950170-23-042631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000095017023042631/glto-20230815.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T09:34:39.171074+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}